Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR506-3p is a tumor-suppressive microRNA (the 3p arm of miR-506) that post-transcriptionally regulates multiple oncogenic pathways by binding complementary sites in target mRNA 3′UTRs and inducing mRNA degradation or translational repression. It is downregulated in several malignancies, including osteosarcoma, pancreatic ductal adenocarcinoma, ovarian cancer, liver cancer, lung cancer, and lung carcinoma, where its restoration via synthetic mimics or agomirs inhibits proliferation, invasion, metastasis, epithelial–mesenchymal transition, and promotes apoptosis, senescence, differentiation, and reactive oxygen species–mediated cell death.[1][3][4][5][6] Identified direct or functional targets include RAB3D and CDK4 in osteosarcoma, PIM-3 and multiple survival/autophagy regulators in pancreatic cancer, CDK4/6–FOXM1 and metastasis-related genes in ovarian cancer, MTMR6 and SIRT1 in liver or lung carcinoma, and a broader “targetome” of differentiation-modulating genes in neuroblastoma, making miR506-3p a candidate therapeutic agent for miRNA replacement or differentiation therapy using nanoparticle or agomir delivery systems.[1][3][4][5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR506-3p.